Intellia Therapeutics (NTLA) Revenue & Revenue Breakdown
Intellia Therapeutics Revenue Highlights
Latest Revenue (Y)
$36.27M
Latest Revenue (Q)
$9.11M
Intellia Therapeutics Revenue by Period
Intellia Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $36.27M | -30.40% |
| 2022-12-31 | $52.12M | 57.69% |
| 2021-12-31 | $33.05M | -43.01% |
| 2020-12-31 | $57.99M | 34.55% |
| 2019-12-31 | $43.10M | 41.63% |
| 2018-12-31 | $30.43M | 16.53% |
| 2017-12-31 | $26.12M | 58.49% |
| 2016-12-31 | $16.48M | 172.65% |
| 2015-12-31 | $6.04M | - |
Intellia Therapeutics generated $36.27M in revenue during NA 2023, up -30.40% compared to the previous quarter, and up 119.19% compared to the same period a year ago.
Intellia Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $9.11M | 30.96% |
| 2024-06-30 | $6.96M | -75.96% |
| 2024-03-31 | $28.93M | -1609.39% |
| 2023-12-31 | $-1.92M | -115.99% |
| 2023-09-30 | $11.99M | -11.78% |
| 2023-06-30 | $13.59M | 7.84% |
| 2023-03-31 | $12.61M | -7.12% |
| 2022-12-31 | $13.57M | 2.31% |
| 2022-09-30 | $13.27M | -5.45% |
| 2022-06-30 | $14.03M | 24.69% |
| 2022-03-31 | $11.25M | -12.46% |
| 2021-12-31 | $12.85M | 78.43% |
| 2021-09-30 | $7.20M | 9.98% |
| 2021-06-30 | $6.55M | 1.63% |
| 2021-03-31 | $6.45M | -2.27% |
| 2020-12-31 | $6.59M | -70.32% |
| 2020-09-30 | $22.22M | 36.63% |
| 2020-06-30 | $16.26M | 25.91% |
| 2020-03-31 | $12.92M | 18.11% |
| 2019-12-31 | $10.94M | 3.01% |
| 2019-09-30 | $10.62M | -4.52% |
| 2019-06-30 | $11.12M | 6.57% |
| 2019-03-31 | $10.43M | 32.40% |
| 2018-12-31 | $7.88M | 6.37% |
| 2018-09-30 | $7.41M | -3.50% |
| 2018-06-30 | $7.68M | 2.78% |
| 2018-03-31 | $7.47M | 12.01% |
| 2017-12-31 | $6.67M | -8.87% |
| 2017-09-30 | $7.32M | 23.66% |
| 2017-06-30 | $5.92M | -4.79% |
| 2017-03-31 | $6.21M | 10.45% |
| 2016-12-31 | $5.63M | 15.57% |
| 2016-09-30 | $4.87M | 15.76% |
| 2016-06-30 | $4.21M | 136.69% |
| 2016-03-31 | $1.78M | 4.96% |
| 2015-12-31 | $1.69M | 0.30% |
| 2015-09-30 | $1.69M | 22.59% |
| 2015-06-30 | $1.38M | 7.08% |
| 2015-03-31 | $1.29M | - |
Intellia Therapeutics generated $9.11M in revenue during Q3 2024, up 30.96% compared to the previous quarter, and up 67.02% compared to the same period a year ago.
Intellia Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.77B |
| BEAM | Beam Therapeutics | $377.71M | $14.27M |
| CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
| DNA | Ginkgo Bioworks | $251.46M | $89.05M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| NTLA | Intellia Therapeutics | $36.27M | $9.11M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $6.87M |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | $39.31M |
| SANA | Sana Bio | - | - |